ERBB2 and ovarian carcinoma: The first clinical study carried out was a phase I trial in which the vaccine integrated the intracellular domain of HER2 plus GM-CSF [69] to evaluate the immunogenicity in patients with HER2-overexpressing breast and ovarian cancers who were in complete remission after being treated, resulting in a promising tolerance [63], immunity maintenance [43], and HER2/neu-specific immunoglobulin G antibody immunity.